Form D · Biotechnology
PHASERX, INC.
Seattle, WA · CIK 0001429386
Offering snapshot reported Jun 9, 2016 · SEC filing
- Reported sold
- $0 Offering amount: $420K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 7, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2016 | Initial | $0 | No comparison | 1 | SEC filing |
| Dec 29, 2015 | Initial | $4,000,000 | No comparison | 17 | SEC filing |
| Dec 17, 2013 | Initial | $0 | No comparison | 4 | SEC filing |
| Oct 2, 2013 | Initial | $1,400,014 | No comparison | 2 | SEC filing |
| Jul 11, 2013 | Initial | $500,005 | No comparison | 1 | SEC filing |
| Dec 21, 2012 | Initial | $1,500,016 | No comparison | 6 | SEC filing |
| Jul 6, 2012 | Initial | $1,600,016 | No comparison | 2 | SEC filing |
| Feb 14, 2012 | Initial | $3,600,037 | No comparison | 5 | SEC filing |
| Feb 22, 2010 | Amendment | $1,216,583 | $913,929vs Aug 26, 2009 | 14 | SEC filing |
| Aug 26, 2009 | Initial | $302,654 | No comparison | 10 | SEC filing |
| Mar 6, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-264676
Total Offering Amount is the amount Issuer may receive upon exercise of warrants. Warrants may be exercised for shares of Common Stock for an aggregate exercise price of (a) an initial $315,000 and, (b) if certain conditions occur, an additional $105,000.
Warrants to purchase Common Stock.
Source: Form D, filed Jun 9, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Atwood | Director |
| Raymond Calvert | Executive |
| John Diekman | Director |
| Steven Gillis | Director |
| Michelle Griffin | Director |
| Michael Houston | Executive |
| Paul Johnson | Director, Executive |
| Andrew Leon | Executive |
| Robert W. Overell | Director, Executive, Promoter |
| John Schmidt | Director |
| Shing Yin (Helen) Tsui | Executive |
| Richard Ulevitch | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
410 West Harrison Street Suite 300
Seattle, WA, 98119
Seattle, WA, 98119